A Phase 1 interventional study of Belantamab mafodotin and Bortezomib in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 11th largest by enrollment, is one of 5 that started in 2019, is one of 11 in phase 1, reaches primary completion later than 14 of the 34 other live ones, and was the 5th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 14th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2019, is one of 12 in phase 1, reaches primary completion later than 13 of the 19 other live ones, and was the 17th registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant should not receive lenalidomide until the investigator has verified that the results of these pregnancy tests are negative. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1.9 milligram /kilogram (mg/kg) Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive 1.4 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Based on emerging data from Cohort 2-5, participants will receive 1.4 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1, followed by 1.0 mg/kg dose on Day 1 of every third cycle from cycle 4 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Based on emerging data from Cohort 2-5, participants will receive 1.9 mg/kg dose of belantamab mafodotin of cycle 1, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 4 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Based on emerging data from Cohort 6-7, participants will receive 1.9 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 4, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 7 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Based on emerging data from Cohort 6-7, participants will receive 1.4 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 3, then 1.0 mg/kg on Day 1 of every third cycle from cycle 6 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Based on emerging data from Cohort 6-7, participants will receive 1.0 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 5, then 1.0 mg/kg on day 1 of every third cycle from cycle 9 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Selected doses of belantamab mafodotin will be administered as intravenous infusion.
Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin
Criteria for DLT included hematologic indicators including Grade(G) 3-5 febrile neutropenia, G4 neutropenia \>7 days, G3 or greater thrombocytopenia accompanied by clinically significant bleeding; non-hematologic criteria, including Any G3/4 non-hematologic toxicity, G5 non hematologic toxicity, G3 or greater corneal toxicity; Liver toxicity meeting prespecified GSK liver stopping criteria. Severity was graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Time frame: Up to 63 days
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 284 weeks
Lenalidomide Relative Dose Intensity (RDI) After Treatment With Belantamab Mafodotin in Combination With VRd
Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).
Time frame: Up to 168 days
Bortezomib RDI After Treatment With Belantamab Mafodotin in Combination With VRd
Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).
Time frame: Up to 168 days
Cumulative Administered Dose of Belantamab Mafodotin After Treatment in Combination With VRd
Cumulative Dose is sum of the actual dose administered during each infusion for a participant.
Time frame: Up to 84 days
Area Under the Concentration Time Curve From 0 to 504 Hours [AUC (0 - 504 Hours)] of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.
Time frame: Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
Maximum Plasma Concentration (Cmax) of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Time to Reach Cmax (Tmax) of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. C-trough were measured prior to the next dose for each cycle.
Time frame: Pre-dose at Day 1 of Cycle 1, 2, 3, 4, 5, 7, 10, 13, 14, 15, 16, 17, 23, 24, 27, 28, 29, 30, 31, 34, 36, 37, 41, 43, 49
Observed Plasma Concentration at the End of Infusion (C-EOI) of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
Time frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
Time of Last Observed Quantifiable Concentration (Tlast) of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive Tlast was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
Clearance of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Volume of Distribution at Steady State (Vss) of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Apparent Terminal Half Life (t1/2) of Belantamab Mafodotin
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
AUC (0 - 504 Hour) of Cys-mcMMAF
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.
Time frame: Day 1 Cycle 1 Pre-Dose, End of Infusion (EOI); Anytime between Day 8 and Day 15 after Start of Infusion (SOI); Cycle 2 Day 1 Pre-Dose (up to Day 22 or at the end of the Cycle 1 dosing period)
Cmax of Cys-mcMMAF
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
Time frame: D1 C1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72h; D8-15 post Start of Infusion(SOI); 22d post-SOI; PD & EOI at D1 of C2-7,10,14-17,19,22,26; PD at D1 of C13,18,21,23,24,27-31,34,36,37,39,41,43,46,49; End of Treatment(EOT) (~C52, up to ~234weeks)
Time to Reach Cmax (Tmax) of Cys-mcMMAF
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI);22 days post-SOI;PD&EOI at D1 of C2-7,C10,C14-17; PD at D1 of C13,C23,C24, C27-29, C34, C39, C46; End of Treatment(~C52,up to ~234weeks)
Observed Plasma C-EOI of Cys-mcMMAF
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
Time frame: End of infusion at Day 1 on C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C24, C25, C26, C27 (up to approximately 81 weeks)
Tlast of Cys-mcMMAF
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
Time frame: Day(D)1 Cycle(C)1 Pre-Dose(PD), End of Infusion(EOI), 2, 24, 72 Hours(h);Anytime D8-15 after Start of Infusion(SOI)
Number of Participants With Positive Post-baseline Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Serum samples were collected for the analysis of ADAs of anti-belantamab mafodotin.
Time frame: Up to approximately 234 weeks
Titers of ADAs Against Belantamab Mafodotin
Serum Samples were collected for the analysis of ADAs of anti-belantamab mafodotin.
Time frame: Up to approximately 234 weeks
Overall Response Rate (ORR)
ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 hour (h); PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200 mg/24 h.
Time frame: Up to approximately 284 weeks
Complete Response Rate (CRR)
CRR is defined as the percentage of participants with a confirmed complete response (CR) or better (i.e. CR and stringent complete response \[sCR\]), according to the IMWG Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Time frame: Up to approximately 284 weeks
Percentage of Participants With Confirmed VGPR or Better
VGPR or better (i.e. VGPR, CR, sCR) is defined as - VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h , CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Time frame: Up to approximately 284 weeks
| Milestone | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 15 | 13 | 19 | 25 | 10 |
| Safety population | 12 | 12 | 12 | 14 | 13 | 18 | 24 | 10 |
| Dlt evaluable population | 0 | 8 | 10 | 8 | 8 | 12 | 13 | 7 |
| Pharmacokinetic population | 12 | 12 | 12 | 13 | 13 | 18 | 24 | 10 |
| Intent-to-treat population | 12 | 12 | 12 | 15 | 13 | 19 | 25 | 10 |
| Completed | 6 | 6 | 4 | 5 | 7 | 9 | 13 | 5 |
| Not completed | 6 | 6 | 8 | 10 | 6 | 10 | 12 | 5 |
| Withdrew: Physician decision | 1 | 1 | 0 | 1 | 2 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 2 | 4 | 2 | 1 | 2 | 0 |
| Withdrew: Ongoing at the time of analysis | 0 | 3 | 6 | 4 | 1 | 7 | 6 | 5 |
| Withdrew: Participants not treated | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Subject reached protocol-defined stopping criteria | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 |
Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).
| Percentage of dose | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Lenalidomide Relative Dose Intensity (RDI) After Treatment With Belantamab Mafodotin in Combination With VRd | 74.45 ± 25.399 | 88.79 ± 30.267 | 77.68 ± 24.414 | 86.44 ± 17.127 | 83.72 ± 18.679 | 72.72 ± 29.635 | 79.20 ± 33.754 | 86.02 ± 55.523 |
Relative Dose Intensity (RDI) is defined as the percentage of the amount of a drug actually delivered (actual dose intensity \[DI\]) relative to the amount planned (planned DI).
| Percentage of dose | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Bortezomib RDI After Treatment With Belantamab Mafodotin in Combination With VRd | 59.39 ± 23.392 | 73.26 ± 16.161 | 72.26 ± 19.320 | 78.03 ± 19.123 | 75.00 ± 22.149 | 70.55 ± 16.258 | 72.04 ± 20.998 | 66.27 ± 17.576 |
Cumulative Dose is sum of the actual dose administered during each infusion for a participant.
| mg | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Cumulative Administered Dose of Belantamab Mafodotin After Treatment in Combination With VRd | 5.03 ± 1.188 | 2.68 ± 0.404 | 3.80 ± 0.808 | 2.67 ± 0.996 | 3.98 ± 1.271 | 2.18 ± 0.536 | 2.91 ± 0.672 | 1.00 ± 0.017 |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.
| ug*h/mL | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration Time Curve From 0 to 504 Hours [AUC (0 - 504 Hours)] of Belantamab Mafodotin | 2627 ± 22.4 | 1861 ± 21.3 | 2556 ± 19.5 | 1410 ± 20.2 | 1870 ± 28.8 | 2385 ± 21.7 | 2960 ± 24.7 | 1620 ± 28.6 |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
| ug/mL | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Belantamab Mafodotin | 29.7 ± 21.9 | 22.5 ± 16.6 | 30.5 ± 16.6 | 16.2 ± 23.2 | 20.8 ± 19.6 | 28.0 ± 15.4 | 34.7 ± 20.0 | 19.4 ± 24.6 |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
| Hours | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) of Belantamab Mafodotin | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) | 0.5 (0.5 to 0.5) |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. C-trough were measured prior to the next dose for each cycle.
| ug/mL | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin | 1.22 ± 38.6 | 0.806 ± 46.7 | 1.18 ± 33.0 | 0.646 ± 42.7 | 0.892 ± 47.7 | 1.24 ± 42.7 | 1.48 ± 40.7 | 0.807 ± 47.0 |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
| ug/mL | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| CYCLE 1 DAY 1 | 28.925 ± 8.4024 | 20.800 ± 4.1492 | 28.600 ± 8.7730 | 22.125 ± 11.5630 | 21.138 ± 4.2116 | 32.778 ± 9.5223 | 38.117 ± 10.6358 | 21.060 ± 6.6650 |
| CYCLE 2 DAY 1 | 31.050 ± 6.3877 | — | — | 18.127 ± 4.9586 | 24.845 ± 7.5900 | 29.700 (NA to NA) | — | — |
| CYCLE 3 DAY 1 | 35.980 ± 10.9461 | 21.670 ± 4.8824 | 29.100 ± 7.1480 | 17.411 ± 5.9610 | 23.404 ± 6.1055 | 28.382 ± 39.9063 | 26.900 ± 1.9799 | — |
| CYCLE 4 DAY 1 | 33.500 ± 6.3640 | — | — | — | — | 21.873 ± 9.2059 | 27.093 ± 11.3974 | — |
| CYCLE 5 DAY 1 | 28.400 ± 8.4859 | 30.780 ± 9.7477 | 33.886 ± 6.7783 | — | — | 25.450 ± 2.8991 | 16.000 (NA to NA) | 20.467 ± 4.2661 |
| CYCLE 6 DAY 1 | — | — | 22.300 (NA to NA) | — | — | 20.900 ± 6.0470 | 33.875 ± 4.8610 | — |
| CYCLE 7 DAY 1 | 33.700 (NA to NA) | 21.567 ± 12.4997 | — | — | 20.050 ± 7.9903 | 19.786 ± 3.7060 | 26.311 ± 5.8610 | 17.400 (NA to NA) |
| CYCLE 8 DAY 1 | — | 15.800 (NA to NA) | — | 20.000 (NA to NA) | — | — | — | — |
| CYCLE 9 DAY 1 | — | 18.100 (NA to NA) | 12.700 (NA to NA) | 15.600 ± 3.3941 | 30.000 (NA to NA) | 17.800 ± 2.6429 | 29.460 ± 5.5833 | 27.788 ± 9.1431 |
| CYCLE 10 DAY 1 | 22.250 ± 4.4548 | — | 30.350 ± 5.3033 | — | 16.250 ± 0.3536 | 21.071 ± 3.9212 | 30.180 ± 10.2683 | — |
| CYCLE 11 DAY 1 | — | 22.000 (NA to NA) | 20.100 ± 8.3439 | — | 19.300 ± 0.0000 | — | 24.400 (NA to NA) | — |
| CYCLE 12 DAY 1 | — | — | 19.300 (NA to NA) | 21.300 (NA to NA) | — | 19.867 ± 4.6004 | — | 24.617 ± 7.9248 |
| CYCLE 13 DAY 1 | — | 38.000 (NA to NA) | — | — | 16.500 (NA to NA) | 19.000 (NA to NA) | 28.400 (NA to NA) | — |
| CYCLE 14 DAY 1 | 27.100 (NA to NA) | — | 19.100 ± 8.3439 | — | — | 22.500 (NA to NA) | — | — |
| CYCLE 15 DAY 1 | 31.467 ± 3.0271 | 22.200 ± 11.4551 | 45.300 (NA to NA) | — | — | 15.567 ± 4.5170 | 43.867 ± 12.1150 | — |
| CYCLE 16 DAY 1 | 20.900 (NA to NA) | — | — | — | — | 25.500 ± 4.6861 | 14.940 ± 2.9416 | 15.700 (NA to NA) |
| CYCLE 17 DAY 1 | 13.300 (NA to NA) | — | 44.700 (NA to NA) | 18.800 (NA to NA) | — | — | — | — |
| CYCLE 18 DAY 1 | — | — | 18.900 (NA to NA) | 27.600 (NA to NA) | — | 19.700 (NA to NA) | — | 19.467 ± 2.9023 |
| CYCLE 19 DAY 1 | — | 32.200 (NA to NA) | — | — | — | 21.500 (NA to NA) | — | — |
| CYCLE 20 DAY 1 | — | — | — | — | — | — | — | 16.500 (NA to NA) |
| CYCLE 21 DAY 1 | — | — | — | 25.800 (NA to NA) | — | — | — | — |
| CYCLE 22 DAY 1 | — | 15.800 (NA to NA) | — | — | — | — | — | — |
| CYCLE 24 DAY 1 | — | — | 19.800 (NA to NA) | — | — | — | — | — |
| CYCLE 25 DAY 1 | — | — | 20.200 (NA to NA) | — | — | — | 26.500 (NA to NA) | — |
| CYCLE 26 DAY 1 | — | 35.400 (NA to NA) | — | — | — | — | — | — |
| CYCLE 27 DAY 1 | — | — | 25.100 (NA to NA) | 18.700 (NA to NA) | — | — | — | — |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin. The last PK assessment used to derive Tlast was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.
| Hours | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Time of Last Observed Quantifiable Concentration (Tlast) of Belantamab Mafodotin | 505 (502 to 526) | 501 (482 to 506) | 501 (477 to 505) | 505 (480 to 507) | 505 (502 to 508) | 501 (492 to 504) | 499 (478 to 503) | 499 (434 to 526) |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
| Liter (L) /Days | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Clearance of Belantamab Mafodotin | 1.1 ± 26.4 | 1.1 ± 40.6 | 1 ± 21.1 | 0.92 ± 27.9 | 0.97 ± 37.3 | 0.84 ± 22.6 | 0.89 ± 36.1 | 0.89 ± 26.8 |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
| Liter | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Volume of Distribution at Steady State (Vss) of Belantamab Mafodotin | 13 ± 17.5 | 12 ± 18.9 | 12 ± 18.5 | 9.9 ± 32.5 | 11 ± 20.3 | 11 ± 29.5 | 9.5 ± 20.3 | 9.1 ± 20.2 |
Blood Samples were collected for Pharmacokinetic analysis of belantamab mafodotin.
| Days | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Apparent Terminal Half Life (t1/2) of Belantamab Mafodotin | 14 ± 23.7 | 14 ± 23.9 | 14 ± 19.1 | 12 ± 37.1 | 13 ± 32.6 | 14 ± 38.4 | 12 ± 20.7 | 11 ± 17.8 |
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF. The last PK assessment used to derive AUC0-504h was intended to be collected approximately 504 hours (21 days) after the start of the first infusion. Depending on the dosing schedule, this assessment occurred either at the Day 22 visit (±3 days) for participants in the Q6/8W and Q9/12W cohorts or at the Cycle 2 Day 1 pre-dose visit for participants in the Q3W cohorts. Therefore, samples collected at Day 22 or Cycle 2 Day 1 predose represent the protocol-defined PK assessment performed at approximately 504 hours after Dose 1.
| ng*h/mL | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| AUC (0 - 504 Hour) of Cys-mcMMAF | 3.66 ± 48.2 | 3.28 ± 114.9 | 3.31 ± 65.5 | 1.9 ± 33.1 | 2.76 ± 27.1 | 3.68 ± 61 | 4.63 ± 54.1 | 2.01 ± 22.5 |
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
| ng/mL | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Cmax of Cys-mcMMAF | 0.7 ± 37.7 | 0.66 ± 111.4 | 0.67 ± 55.2 | 0.38 ± 50.1 | 0.57 ± 50.1 | 0.68 ± 80.7 | 0.91 ± 56.6 | 0.4 ± 31.9 |
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
| Hours | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) of Cys-mcMMAF | 24 (0.5 to 72) | 24 (24 to 24) | 24 (24 to 24) | 24 (24 to 24) | 24 (24 to 24) | 24 (24 to 72) | 24 (24 to 24) | 24 (24 to 24) |
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
| ng/mL | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| CYCLE 1 DAY 1 | 0.251 ± 0.1299 | 0.260 ± 0.0846 | 0.351 ± 0.1893 | 0.184 ± 0.1399 | 0.289 ± 0.1751 | 0.272 ± 0.1134 | 0.349 ± 0.1792 | 0.568 ± 1.4345 |
| CYCLE 2 DAY 1 | 0.263 ± 0.1018 | — | — | 0.142 ± 0.0339 | 0.270 ± 0.1468 | 0.256 (NA to NA) | — | — |
| CYCLE 3 DAY 1 | 0.353 ± 0.1246 | 0.304 ± 0.2316 | 0.338 ± 0.1281 | 0.129 ± 0.0241 | 0.189 ± 0.1143 | 0.095 ± 0.1344 | 0.119 ± 0.0350 | — |
| CYCLE 4 DAY 1 | 0.438 ± 0.1492 | — | — | — | — | 0.153 ± 0.0568 | 0.226 ± 0.1413 | — |
| CYCLE 5 DAY 1 | 0.225 ± 0.0284 | 0.245 ± 0.1254 | 0.251 ± 0.0912 | — | — | 0.153 ± 0.0042 | 0.248 (NA to NA) | 0.127 ± 0.0464 |
| CYCLE 6 DAY 1 | — | — | 0.619 (NA to NA) | — | — | 0.140 ± 0.0391 | 0.171 ± 0.0537 | — |
| CYCLE 7 DAY 1 | 0.200 (NA to NA) | 0.074 ± 0.0699 | — | — | 0.119 ± 0.0482 | 0.138 ± 0.0437 | 0.193 ± 0.0729 | 0.090 (NA to NA) |
| CYCLE 8 DAY 1 | — | 0.155 (NA to NA) | — | 0.192 (NA to NA) | — | — | — | — |
| CYCLE 9 DAY 1 | — | 0.141 (NA to NA) | 0.457 (NA to NA) | 0.276 ± 0.2298 | 0.180 (NA to NA) | 0.118 ± 0.0571 | 0.228 ± 0.0954 | 0.137 ± 0.0620 |
| CYCLE 10 DAY 1 | 0.178 ± 0.0976 | — | 0.168 ± 0.0495 | — | 0.137 ± 0.0555 | 0.125 ± 0.0464 | 0.124 ± 0.0322 | — |
| CYCLE 11 DAY 1 | — | 0.195 (NA to NA) | 0.420 ± 0.4835 | — | 0.272 ± 0.1874 | — | 0.163 (NA to NA) | — |
| CYCLE 12 DAY 1 | — | — | 0.153 (NA to NA) | 0.114 (NA to NA) | — | 0.154 ± 0.0679 | — | 0.090 ± 0.0632 |
| CYCLE 13 DAY 1 | — | 0.306 (NA to NA) | — | — | 0.164 (NA to NA) | 0.104 (NA to NA) | 0.105 (NA to NA) | — |
| CYCLE 14 DAY 1 | 0.325 (NA to NA) | — | 0.124 ± 0.0364 | — | — | 0.105 (NA to NA) | — | — |
| CYCLE 15 DAY 1 | 0.242 ± 0.1408 | 0.137 ± 0.0233 | 0.117 (NA to NA) | — | — | 0.082 ± 0.0226 | 0.219 ± 0.0900 | — |
| CYCLE 16 DAY 1 | 0.507 (NA to NA) | — | — | — | — | 0.105 ± 0.0162 | 0.097 ± 0.0263 | 0.063 (NA to NA) |
| CYCLE 17 DAY 1 | 0.309 (NA to NA) | — | 0.384 (NA to NA) | 0.188 (NA to NA) | — | — | — | — |
| CYCLE 18 DAY 1 | — | — | 0.192 (NA to NA) | 0.188 (NA to NA) | — | 0.112 (NA to NA) | — | 0.088 ± 0.0253 |
| CYCLE 19 DAY 1 | — | 0.120 (NA to NA) | — | — | — | 0.071 (NA to NA) | — | — |
| CYCLE 20 DAY 1 | — | — | — | — | — | — | — | 0.064 (NA to NA) |
| CYCLE 21 DAY 1 | — | — | — | 0.150 (NA to NA) | — | — | — | — |
| CYCLE 22 DAY 1 | — | 0.123 (NA to NA) | — | — | — | — | — | — |
| CYCLE 24 DAY 1 | — | — | 0.192 (NA to NA) | — | — | — | — | — |
| CYCLE 25 DAY 1 | — | — | 0.128 (NA to NA) | — | — | — | 0.242 (NA to NA) | — |
| CYCLE 26 DAY 1 | — | 0.238 (NA to NA) | — | — | — | — | — | — |
| CYCLE 27 DAY 1 | — | — | 0.095 (NA to NA) | 0.273 (NA to NA) | — | — | — | — |
Blood Samples were collected for Pharmacokinetic analysis of cys-mcMMAF.
| Hours | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Tlast of Cys-mcMMAF | 168 (68 to 241) | 167 (71.5 to 210) | 165 (3.02 to 193) | 165 (67.1 to 236) | 167 (2 to 237) | 165 (67.7 to 331) | 165 (2.22 to 238) | 165 (67.2 to 190) |
Serum samples were collected for the analysis of ADAs of anti-belantamab mafodotin.
| Participants | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Positive Post-baseline Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
Serum Samples were collected for the analysis of ADAs of anti-belantamab mafodotin.
| Titers | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Titers of ADAs Against Belantamab Mafodotin | — | — | — | 400.0 | 100.0 | — | 100.0 | — |
ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 hour (h); PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200 mg/24 h.
| Percentage of Participants | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 100 (73.5 to 100.0) | 92 (61.5 to 99.8) | 100 (73.5 to 100.0) | 80 (51.9 to 95.7) | 92 (64.0 to 99.8) | 84 (60.4 to 96.6) | 80 (59.3 to 93.2) | 100 (69.2 to 100.0) |
CRR is defined as the percentage of participants with a confirmed complete response (CR) or better (i.e. CR and stringent complete response \[sCR\]), according to the IMWG Response Criteria. CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
| Percentage of Participants | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Complete Response Rate (CRR) | 75 (42.8 to 94.5) | 83 (51.6 to 97.9) | 92 (61.5 to 99.8) | 67 (38.4 to 88.2) | 62 (31.6 to 86.1) | 58 (33.5 to 79.7) | 48 (27.8 to 68.7) | 90 (55.5 to 99.7) |
VGPR or better (i.e. VGPR, CR, sCR) is defined as - VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h , CR: negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR: CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
| Percentage of Participants | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Confirmed VGPR or Better | 92 (61.5 to 99.8) | 92 (61.5 to 99.8) | 100 (73.5 to 100.0) | 73 (44.9 to 92.2) | 92 (64.0 to 99.8) | 74 (48.8 to 90.9) | 68 (46.5 to 85.1) | 100 (69.2 to 100.0) |
Criteria for DLT included hematologic indicators including Grade(G) 3-5 febrile neutropenia, G4 neutropenia \>7 days, G3 or greater thrombocytopenia accompanied by clinically significant bleeding; non-hematologic criteria, including Any G3/4 non-hematologic toxicity, G5 non hematologic toxicity, G3 or greater corneal toxicity; Liver toxicity meeting prespecified GSK liver stopping criteria. Severity was graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
| Participants | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab Mafodotin | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 12 | 12 | 12 | 14 | 13 | 18 | 24 | 10 |
Collected over All cause mortality, non-SAEs and SAEs were collected upto approximately 284 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | 2/12 (16.7%) | 11/12 (91.7%) | 12/12 (100%) |
| Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | 4/12 (33.3%) | 10/12 (83.3%) | 12/12 (100%) |
| Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | 1/12 (8.3%) | 11/12 (91.7%) | 12/12 (100%) |
| Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | 0/14 (0%) | 8/14 (57.1%) | 14/14 (100%) |
| Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | 2/13 (15.4%) | 6/13 (46.2%) | 13/13 (100%) |
| Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | 5/18 (27.8%) | 13/18 (72.2%) | 18/18 (100%) |
| Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | 2/24 (8.3%) | 14/24 (58.3%) | 23/24 (95.8%) |
| Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd | 0/10 (0%) | 7/10 (70%) | 10/10 (100%) |
| Event | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 2/12 | 3/12 | 5/12 | 2/14 | 1/13 | 2/18 | 2/24 | 1/10 |
| PneumoniaInfections and infestations | 4/12 | 2/12 | 2/12 | 0/14 | 2/13 | 2/18 | 2/24 | 2/10 |
| BronchitisInfections and infestations | 0/12 | 0/12 | 0/12 | 0/14 | 0/13 | 0/18 | 0/24 | 2/10 |
| Femur fractureInjury, poisoning and procedural complications | 0/12 | 2/12 | 0/12 | 0/14 | 0/13 | 0/18 | 1/24 | 0/10 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/12 | 2/12 | 1/12 | 0/14 | 0/13 | 1/18 | 0/24 | 1/10 |
| PyrexiaGeneral disorders | 2/12 | 0/12 | 0/12 | 1/14 | 1/13 | 1/18 | 0/24 | 0/10 |
| Orthostatic hypotensionVascular disorders | 2/12 | 0/12 | 0/12 | 0/14 | 0/13 | 0/18 | 0/24 | 0/10 |
| COVID-19Infections and infestations | 0/12 | 0/12 | 1/12 | 2/14 | 1/13 | 0/18 | 2/24 | 0/10 |
| Lower respiratory tract infectionInfections and infestations | 0/12 | 1/12 | 0/12 | 2/14 | 0/13 | 0/18 | 1/24 | 1/10 |
| Back painMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 1/12 | 2/14 | 0/13 | 0/18 | 0/24 | 0/10 |
| Event | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 2/12 | 7/12 | 10/12 | 3/14 | 3/13 | 5/18 | 5/24 | 1/10 |
| Vision blurredEye disorders | 7/12 | 7/12 | 6/12 | 5/14 | 7/13 | 2/18 | 7/24 | 7/10 |
| ConstipationGastrointestinal disorders | 8/12 | 5/12 | 5/12 | 6/14 | 6/13 | 1/18 | 6/24 | 3/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/12 | 8/12 | 6/12 | 6/14 | 7/13 | 8/18 | 11/24 | 6/10 |
| Neuropathy peripheralNervous system disorders | 5/12 | 5/12 | 2/12 | 4/14 | 8/13 | 4/18 | 4/24 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 6/12 | 7/12 | 6/12 | 6/14 | 8/13 | 7/18 | 9/24 | 5/10 |
| Oedema peripheralGeneral disorders | 6/12 | 4/12 | 5/12 | 4/14 | 6/13 | 2/18 | 7/24 | 6/10 |
| Peripheral sensory neuropathyNervous system disorders | 2/12 | 7/12 | 7/12 | 3/14 | 2/13 | 6/18 | 5/24 | 3/10 |
| InsomniaPsychiatric disorders | 7/12 | 3/12 | 1/12 | 2/14 | 2/13 | 5/18 | 3/24 | 4/10 |
| Dry eyeEye disorders | 4/12 | 3/12 | 6/12 | 4/14 | 4/13 | 2/18 | 5/24 | 4/10 |
| Age, Continuous(YEARS) | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 71.5 ± 4.78 | 73.1 ± 3.45 | 73.5 ± 2.84 | 71.1 ± 8.35 | 74.5 ± 5.61 | 71.6 ± 9.14 | 76.2 ± 6.15 | 75.3 ± 5.03 | 73.5 ± 6.46 |
| Sex: Female, Male(Participants) | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 6 | 6 | 8 | 5 | 7 | 12 | 5 | 53 |
| Male | 8 | 6 | 6 | 7 | 8 | 12 | 13 | 5 | 65 |
| Race (NIH/OMB)(Participants) | Cohort 1: Belantamab Mafodotin 1.9 Milligram/ Kilogram (mg/kg) Q3/4W + VRd/Rd | Cohort 2: Bela 1.4 mg/kg Q6/8W + VRd/Rd | Cohort 3: Bela 1.9 mg/kg Q6/8W + VRd/Rd | Cohort 4: Bela 1.0 mg/kg Q3/4W + VRd/Rd | Cohort 5: Bela 1.4 mg/kg Q3/4W + VRd/Rd | Cohort 6: Bela 1.4 mg/kg Followed by 1.0 mg/kg Q9W/12W+VRd/Rd | Cohort 7: Bela 1.9 mg/kg Followed by 1.4 mg/kg Q9W/12W + VRd/Rd | Cohort 8: Bela 1.0 mg/kg Q12W + VRd/Rd | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 | 2 | 2 | 0 | 1 | 0 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| White | 10 | 10 | 8 | 12 | 11 | 19 | 23 | 10 | 103 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Dec 2019 to primary completion in Jun 2025, 65 months.
Results were first posted in Nov 2026, 1 year 5 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 65 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2028, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab mafodotin